BioCentury on BioBusiness,
Neurex adds a late stage product
Monday, July 18, 1994
Neurex adds a late-stage product
Neurex Corp. was to announce today the acquisition of Creagen, a Boston-based company
developing the thrombolytic agent Pro-Urokinase and Walk Through Mutagenesis technology
for protein engineering.
NXCO will issue 1.95 million shares of common stock in exchange for all of the shares
outstanding of Creagen, giving Creagen shareholders a 16 percent stake in the Menlo Park,
Calif., company. Prior to the deal, NXCO has 10.3 million shares outstanding. The stock
closed at $4.375 on Friday.
The deal accomplishes two interrelated goals for NXCO. It obtains a second late-stage
product behind its lead compound, Corlopam (fenoldopam), which was in-licensed to treat
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]